Sulzermedica faces higher patent damages:
This article was originally published in Clinica
Swiss medical device company Sulzermedica is facing higher patent infringement damages than expected if it loses its appeal. A court of first instance has set damages payable to Stryker (US) at $73 million, compared with original estimates of some $50 million. The news is contained in the third quarter results of Sulzer, Sulzermedica's engineering parent, which repeats earlier warnings that 1995 profits will be below last year's SwFr 195 million ($160 million). Sulzer's nine-month group sales were 2% up on the previous year at SwFr 4,252 million. Sulzermedica's turnover was 3% down at SwFr 769 million, which, nevertheless corresponds to a 13% increase when expressed in US dollars.
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.